Related Experiment Videos
Saliva carbamazepine and phenytoin level monitoring
Insights
Saliva drug monitoring for carbamazepine and phenytoin in children showed that high levels correlated with adverse effects. However, saliva levels did not reliably predict seizure control for either medication.
Area of Science:
- Pharmacology
- Pediatric Medicine
- Clinical Chemistry
Background:
- Therapeutic drug monitoring (TDM) is crucial for optimizing antiepileptic drug efficacy and safety in children.
- Saliva drug levels offer a non-invasive alternative to serum monitoring for certain medications.
- Carbamazepine and phenytoin are commonly prescribed antiepileptic drugs in pediatric populations.
Purpose of the Study:
- To evaluate the utility of saliva carbamazepine and phenytoin levels for therapeutic drug monitoring in children.
- To assess the relationship between saliva drug concentrations, adverse effects, and seizure control.
- To determine the correlation between drug dosage and saliva drug levels.
Main Methods:
- Saliva samples were collected from 35 children (aged 2-14 years) over a 2-year period.
- Carbamazepine and phenytoin levels in saliva were measured.
- Association between saliva levels, adverse effects, and convulsion control was analyzed.
- Correlation between drug dosage and saliva levels was examined.
Main Results:
- Elevated phenytoin and over half of elevated carbamazepine saliva levels were linked to adverse effects.
- A significant correlation was observed between carbamazepine dosage and saliva levels.
- No significant relationship was found between phenytoin dosage and saliva levels.
- Saliva drug levels did not show a clear relationship with seizure control for either drug.
Conclusions:
- Saliva monitoring may indicate potential toxicity for carbamazepine and phenytoin in children.
- Saliva drug levels are not a reliable indicator of seizure control in this pediatric cohort.
- Further research is needed to establish the role of saliva TDM for antiepileptic drugs in pediatrics.
Abstract:
Saliva carbamazepine and phenytoin samples were used to monitor treatment in 35 children aged between 2 and 14 years during a 2-year period. All phenytoin levels and over half the carbamazepine levels that were above the therapeutic range were associated with adverse effects. Dose and carbamazepine saliva levels were significantly related but no such relationship was found for phenytoin. There was no apparent relationship between the saliva level of either drug and convulsion control.